Baxter FDA Friday, August 14, 1987 +0.20 Positive

FDA Approves IFOSFAMIDE — Baxter Healthcare Company

Baxter Healthcare Company has been granted regulatory confirmation for its intravenous formulation of ifosfamide, a product first approved in 1987, which bolsters its long-standing portfolio of oncology treatments and reinforces its competitive positioning within the market. This historic nod—underscored by the specific regulatory reference NDA019763—serves as a strategic validation for Baxter, maintaining the drug's sustained relevance as a critical chemotherapeutic agent.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed